Insmed Highlights Brensocatib 25mg’s 8.4-Point QOL-B RSS Gain at ATS 2026
INSM•At ATS 2026, Insmed presented Phase III ASPEN post-hoc analysis showing brensocatib 25mg improved mean QOL-B RSS from 61.9 to 70.3 at week 52 versus 66.3 for placebo. A patient survey of 1,050 NCFB cases found 76.8% reported health declines after exacerbations and widespread anxiety about future flares.
1. Phase III ASPEN Trial Post-hoc Analysis
At the 2026 American Thoracic Society conference, Insmed presented a post-hoc analysis of the Phase III ASPEN trial in adult NCFB patients, showing brensocatib 10mg and 25mg doses improved mean QOL-B RSS from baseline to week 52 versus placebo (10mg: 59.8→67.9; 25mg: 61.9→70.3; placebo: 60.0→66.3). Improvements were most pronounced in the 25mg group across pulmonary exacerbation subgroups, underscoring dose-dependent efficacy in reducing respiratory symptoms.
2. Survey Reveals NCFB Patient Burden
A multicenter survey of 1,050 NCFB patients and 88 caregivers across the US and Europe revealed that 76.8% of patients experienced health status declines following exacerbations, with significant emotional and social impact. Even among patients without recent exacerbations, anxiety about potential future flares was widespread, highlighting the need for improved patient support and treatment pathways.
3. Ongoing Awareness and Diagnosis Initiatives
Insmed supported an ATS initiative in April 2026 to mine electronic health records from seven academic centers over 36 months to identify undiagnosed bronchiectasis cases. In May 2026, the company launched the “Suspect Bronchiectasis” educational program to raise awareness of key respiratory symptoms and prompt proper diagnosis, aiming to enhance early detection and care.
